Alternate Name(s):
Xevudy
Classification:
Anti-SARS-CoV-2 spike protein monoclonal antibody
Original Date:
January 2022
Indications:
- Treatment of mild to moderate Covid-19 in patients ≥12 years weighing ≥40 kg who are at high risk fop regressing to hospitalization and/or death
Reconstitution and Stability:
- Available as a 500mg/8mL solution
- Store undiluted vials in refrigerator and protect from light
- Allow vial to equilibrate to room temperature for 15 minutes prior to use
- Gently swirl the vial several times before use without creating air bubbles. Do not shake or vigorously agitate the vial.
- From a 100 mL bag of 0.9% NaCl, remove 18 mL(8mL + 10mL overfill) for a final volume of 92 mL
- Withdraw 8 mL from the vial of sotrovimab.
- Inject the 8 mL of sotrovimab into the infusion bag
- Prior to the infusion, gently rock the infusion bag back and forth 3 to 5 times. Do not invert the infusion bag. Avoid forming air bubbles.
- Vial stability once diluted: 6 hours room temperature OR 24 hours refrigerated
Compatibility:
- Solutions Compatible: 0.9% Sodium Chloride, Dextrose 5%
- Additives/Above Cassette Compatible: No information
-
Y-site Compatible: No information
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | NO |
| IM | NO |
| IV Direct | NO |
| IV Intermittent Infusion |
YES Infusion Time: 60 minutes |
| IV Continuous Infusion | NO |
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- Patients ≥12 years and weighing ≥40 kg: 500mg IV dose once
Potential hazards of parenteral administration:
- Hypersensitivity, including anaphylaxis, reactions
- Infusion related reactions
Notes:
- Contraindicated in patients with hypersensitivity to sotrovimab or any non-medicinal ingredients in the formulation
- Not authorized for treatment of patients younger than 12 years old or those weighing less than 40 kg
- Sotrovimab may diminish the effects of the COVID-19 Vaccine. If patient is due a vaccine, wait at least 90 days after receiving sotrovimab or other monoclonal antibodies used for the treatment of COVID-19.
References:
- Sotrovimab Health Canada drug product monograph